AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02965924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine 2.5%
Description: Instilling phenylephrine 2.5% eye drop
Study NCT03343548 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium sulfate
Description: 2cc of magnesium sulfate ( 50%) will be administered epidurally
Study NCT03343548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 2cc of normal saline will be administered epidurally
Study NCT02282462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reg Pressure
Description: Regulated Suction using the Thopaz+ digital chest drainage device
Study NCT02282462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unreg Pressure
Description: Unregulated Suction using a traditional system (multi-chambered system e.g. Pleur-Evac, Atrium-Maquet or similar device as is routine at each institution)
Study NCT03154853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: short foot exercise
Description: Behavioral: short foot exercise 30 repetitions per section (10 seconds for each contraction, 1 minute between sections), 3 times/ week, 3 weeks
Study NCT02815878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhance Wellness
Description: A 6-month health promotion intervention which pairs participants with a wellness coach to identify and pursue a health-related goal of their choosing.
Study NCT02815878 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhance Wellness
Description: A 6-month health promotion intervention which pairs participants with a wellness coach to identify and pursue a health-related goal of their choosing.
Study NCT03325530 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group with Participants
Description: Focus groups with leaders (18+) to investigate tolerance to healthy initiatives
Study NCT02864758 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Tablets, 20mg once daily
Study NCT02864758 — intervention group
Intervention type: DRUG
Intervention: Vitamin K antagonists
Description: Tablets, dose is based on International Normalized Ratio
Study NCT02864758 — intervention group
Intervention type: DRUG
Intervention: dabigatran (Pradaxa)
Description: Tablets, 150 mg twice daily
Study NCT01048320 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: The starting dose of gemcitabine will be 400 mg/m2 on day 1 of a two-week cycle.~Gemcitabine is given on day 1 every two weeks according to the dose escalation schedule below:~Dose level -1 200mg/m2 Dose level 1 400mg/m2 Dose level 2 600mg/m2 Dose level 3 800mg/m2 Dose level 4 1000mg/m2 Dose level 5 1000mg/m2 It is administered as an intravenous infusion, the lyophilized powder being diluted in normal saline, at a fixed dose of 10 mg/m2/minute.
Study NCT01048320 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Oxaliplatin is given by intravenous infusion on day 2 every 2 weeks according to the dose escalation schedule below: Dose level -1 - 4 85mg/m2 Dose level 5 100mg/m2 Oxaliplatin should be diluted in 250 to 500 ml of 5% glucose solution to give a concentration not less than 0.2 mg/ml. It must be infused via a central venous line or peripheral vein over 2 hours. In the event of extravasation, administration must be discontinued immediately and the extravasation managed according to local procedures.
Study NCT01048320 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib
Description: Imatinib is given for 7 days every cycle starting 2 days before the gemcitabine is given, including administration on days 1 and 2 when gemcitabine and oxaliplatin are given, and for 3 days afterwards (i.e. days -2 to +5). It is thus given on a 7 days on and 7 days off intermittent dosing schedule. The dose will be fixed at 400 mg daily in tablet form and taken once daily with food.~Imatinib should commence either in the morning or lunchtime of day -2 and be taken at the same time daily for seven consecutive days in total.
Study NCT02282462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Suction (Dig)
Description: Thopaz+ digital chest drainage device set at -20cmH2O at the patient
Study NCT02282462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Suction (Trad)
Description: Pleur-Evac, Atrium-Maquet or similar set at -20cmH2O at the device.
Study NCT02282462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Drainage (Dig)
Description: Thopaz+ digital chest drainage device set at -8cmH2O at the patient (physiologic)
Study NCT02282462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Drainage (Trad)
Description: Pleur-Evac, Atrium-Maquet or similar set by gravity (water-seal')
Study NCT03955172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Patients will received everolimus (CERTICAN), oral form, at the necessary dose to obtain trough levels between 6 and 8 ng/ml, during 6 months. Everolimus will replace the anti-proliferative drug they have before (azathioprine or mycophenolic acid). Everolimus will be associated with corticosteroids (prednisolone) and a calcineurin inhibitor (tacrolimus or cyclosporin).
Study NCT00289211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] (C1INH-nf)
Study NCT00289211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Study NCT02151721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat, gefitinib
Description: Vorinostat 200, 300, or 400 mg orally once daily on days 1-7 with washout on days 8-14 plus gefitinib 250 mg orally once daily on days 1-14
Study NCT03668106 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sperm processing method
Description: different sperm processing method for selcting most proper sperm for ICSI
Study NCT01726166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprapubic Aspiration
Description: Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
Study NCT01726166 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urinary Catheterization
Description: Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
Study NCT01033136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Channel Exposure Therapy - Veterans
Description: MCET-V offers individual therapy that provides psychoeducation about panic attacks and trauma and involves behavioral and cognitive exposure exercises.
Study NCT01033136 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: CPT offers individual therapy that targets trauma and PTSD symptoms via cognitive restructuring.
Study NCT00017251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00017251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00017251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00017251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00017251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00243243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Factor VIIa
Description: intravenous infusion of Factor VIIa
Study NCT00243243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion of placebo (sterile water)
Study NCT03477656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Large volume specific immunoadsorption
Description: 1 to 2 sessions of large volume specific immunoadsorption using GLYCOSORB®-ABO column
Study NCT03477656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double Filtration Plasmapheresis
Description: 1 to 5 sessions of double filtration plasmapheresis
Study NCT00454298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AGG-523 (Aggrecanase Inhibitor)
Study NCT00454298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGG-523 (Aggrecanase Inhibitor)
Study NCT02758418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAO
Description: TAO is a self-applied online treatment program and consists on the computerized version of the traditional CBT protocol for Adjustment Disorders.~The treatment protocol comprises different therapeutic components (see section Intervention) which are presented to the patients through 7 modules (one of them introductory). The Internet platform allows audiovisual resources (videos, illustrations, music and exercises that provide quick feedback) to be included, that makes the program more interactive.
Study NCT00000575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.
Study NCT00000575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nedocromil
Description: Four 2 mg puffs bid + two 90 Og puffs albuterol prn
Study NCT00000575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Two 100 Og puffs bid + two 90 Og puffs albuterol prn.
Study NCT05198141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets
Description: GI: Patients who were undergoing laparoscopic salpingectomy GII: patients who medically treated with 5 mg d-1 of letrozole using two tablets (2.5 mg of Femara) every day for 10 d GIII patients who medically treated with 10 mg d-1 of letrozole using four tablets (2.5 mg of Femara) every day for 10 d (group III)
Study NCT05198141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic salpingectomy
Description: laparoscopic salpingectomy
Study NCT03002896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pep-Pal
Description: Pep-Pal is designed to complement the utilization of other resources, provide support when no other resources can be obtained, or provide support in the interim until greater resources can be obtained. In this way, Pep-Pal is a resource for our most hard to reach caregivers.
Study NCT03002896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Study NCT03002896 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study NCT04409613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and counseling
Description: All patients or their caregivers will receive twenty minutes educational sessions for the first three visits according to patient ability to understand. At subsequent visits along the study duration, we will briefly review our educational material to refresh the patient's information. This will include: The objectives of treatment, disease progression process, risk factors, common symptoms of bleeding/thrombotic events and how to deal with this. Lifestyle modifications, including smoking cessation, blood pressure and diabetes control. Drug information: drug action, dose, indication, possible side effects, how to deal with the side effects, actions to take when missing the dose, storage conditions and when and how to administer. Possible interactions including drug-drug and drug-food interactions. Target INR and INR monitoring
Study NCT02146183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate steviol glycosides
Description: To investigate if intake of stevioside in addition to a carbohydrate-containing composition after work related depletion of muscle glycogen will increase the rate of glycogen re-synthesis as compared with intake of the carbohydrate-containing composition alone.
Study NCT02146183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Corn Starch
Description: 500 mg/day
Study NCT00833326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Description: multiple dose, escalating
Study NCT00833326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, mitotic inhibitor; intravenous
Description: multiple dose, single schedule
Study NCT00833326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic growth factors; subcutaneous
Description: standard of care
Study NCT02294266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mephedrone and alcohol
Description: Single oral dose mephedrone~Single oral dose alcohol
Study NCT02294266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mephedrone
Description: Single oral dose mephedrone
Study NCT02294266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Single oral dose alcohol
Study NCT02294266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose placebo
Study NCT03807024 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: 3-day bladder diary: The classification of OAB-wet or OAB-dry is based on the record of the three-day bladder diary of each patient. The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet, otherwise, OAB-dry
Study NCT03384199 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose escalation to prostate focal lesion
Description: For each patient the radio-opaque marker (used for treatment verification) will be inserted by ultrasound guidance \& local anaesthetic with an 17ga x 30cm brachytherapy needle that has 1.2mm x 3mm one gold marker. The ultrasound probe (as used for transrectal biopsy) will be introduced rectally with the patient in the left lateral position. After measuring the volume of the prostate and determining the desired position (preferably in the corpus of prostate), three gold markers will be inserted as follows: one into right side, one into left side of the base and the third in the apex of the prostate
Study NCT02474186 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy
Study NCT02474186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: chemotherapy agent daily for two weeks
Study NCT02474186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: chemotherapy agent weekly for two weeks
Study NCT00437463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: 2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
Study NCT01478659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control study food with no added fiber
Description: Adults consuming their usual diet modified by incorporating yogurt and snack bars without added fiber.
Study NCT01478659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Study food with added fiber
Description: Adults consuming their usual diet modified by incorporating yogurt and snack bars containing 16 g of chicory root fiber (Frutalose®).
Study NCT00293592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 1 mg per kg as a single dose before initiation of cardiopulmonary bypass
Study NCT00293592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: 1 mg per kg as a single dose before initiation of cardiopulmonary bypass
Study NCT02770703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DynaMesh visible mesh
Description: Implantation of a MRI visible mesh
Study NCT02218463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol cream 0.01%
Description: Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
Study NCT02218463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetaphil
Description: Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
Study NCT04422067 — intervention group
Intervention type: OTHER
Intervention: Fetal cephalometry
Description: Fetal cephalometry
Study NCT01642381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Full Motivational Interviewing (FMI)
Description: Relational and technical technical (directive) strategies in counselling sessions to significantly increase commitment strength to reduce drinking.
Study NCT01642381 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spirit Only Motivational Interviewing (SOMI)
Description: Empathic and non-directive counselling based on Rogerian psychotherapy model.
Study NCT04163874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fiasp
Description: Fiasp Insulin delivered in a basal-bolus manner.
Study NCT04163874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fiasp
Description: Fiasp Insulin delivered in a basal-bolus manner.
Study NCT04163874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fiasp
Description: Fiasp Insulin delivered in a basal-bolus manner.
Study NCT04163874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide Acetate
Description: Pramlintide delivered in a basal-bolus manner with a fixed ratio with insulin.
Study NCT04163874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo delivered in a basal-bolus manner with a fixed ratio with insulin.
Study NCT04163874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered in a basal-bolus manner with a fixed ratio with insulin.
Study NCT04163874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: Tandem insulin pump, dexcom G5 sensor, Nexus 5 cellphone running the iMAP algorithm.
Study NCT04163874 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Artificial Pancreas
Description: Tandem insulin pump, dexcom G5 sensor, Nexus 5 cellphone running the iMAP algorithm.
Study NCT04163874 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Pancreas
Description: Tandem insulin pump, dexcom G5 sensor, Nexus 5 cellphone running the iMAP algorithm.
Study NCT01389778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: Metformin ER 1500 mg for 12 weeks
Study NCT01389778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT00259103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Study NCT00259103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03832556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT scan
Description: CT scan with biphasic injection of contrast product
Study NCT03832556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI examination
Description: MRI with injection of contrast
Study NCT06243302 — intervention group
Intervention type: PROCEDURE
Intervention: OTSC Closure After VAAFT
Description: Under general anesthesia,the fistulas will be drained at least for 8 weeks. Then a video camera will be inserted through the external opening to fulgurate the fistula tract under direct vision. Finally the internal fistula opening will be closed water tight by a circular clip. The patients will be followed up for complications as well as short and long term recurrences
Study NCT02634255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium elective surgery
Description: Rocuronium onset time in patients undergoing inguinal herniorrhaphy
Study NCT02634255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium emergency surgery
Description: Rocuronium onset time in patients undergoing appendectomy
Study NCT02634255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT02634255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study NCT02634255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT02634255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study NCT02634255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ringer Lactate
Study NCT02634255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ringer Lactate
Study NCT02634255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acceleromyography device
Study NCT02634255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acceleromyography device
Study NCT02060409 — intervention group
Intervention type: GENETIC
Intervention: spliceosome
Description: spliceosome mutations